Yvon Ruch1,2, Yves Hansmann3, Philippe Riegel4, Nicolas Lefebvre3, Jean-Philippe Mazzucotelli5, Nawal Douiri3, Aurélie Martin3, Xavier Argemi3. 1. Department of Infectious Disease, Strasbourg University Hospital, Strasbourg, France. yvon.ruch@gmail.com. 2. Service de Maladies Infectieuses et Tropicales, Centre Hospitalo, Universitaire de Strasbourg, 1 place de l'hôpital, BP 426, 67091, Strasbourg Cedex, France. yvon.ruch@gmail.com. 3. Department of Infectious Disease, Strasbourg University Hospital, Strasbourg, France. 4. Laboratory of Bacteriology, Strasbourg University Hospital, Strasbourg, France. 5. Department of Cardiovascular Surgery, Strasbourg University Hospital, Strasbourg, France.
Abstract
BACKGROUND: Streptococci involved in infective endocarditis (IE) primarily comprise alpha- or non-hemolytic streptococci (ANHS). Moreover, beta-hemolytic streptococci (BHS) can be involved, and guidelines recommend the addition of gentamicin for the first 2 weeks of treatment and the consideration of early surgery in such cases. This study compared the morbidity and mortality associated with IE depending on the microorganisms involved (BHS, ANHS, staphylococci, and enterococci). METHODS: We conducted a retrospective observational study between 2012 and 2017 in a single hospital in France. The endpoints were overall in-hospital mortality, 1-year mortality and the occurrence of complications. RESULTS: We analyzed 316 episodes of definite IE including 150 (38%), 96 (25%), 46 (12%), and 24 cases (6%) of staphylococcal, ANHS, enterococcal, and BHS IE, respectively. In-hospital mortality was significantly higher in the staphylococcal (n = 40; 26.7%) and BHS groups (n = 6; 25.0%) than in the ANHS (n = 9; 9.4%) and enterococcal groups (n = 5; 10.9%) (all p < 0.01). The rates of septic shock and cerebral emboli were also higher in the BHS group than in the ANHS group [n = 7 (29.2%) vs. n = 3 (3.1%), p < 0.001; n = 7 (29.2%) vs. n = 12 (12.5%); p = 0.05, respectively]. CONCLUSION: This study confirmed that BHS IE has a more severe prognosis than ANHS IE. The virulence of BHS may be similar to that of staphylococci, justifying increased monitoring of these patients and more 'aggressive' treatments such as early surgery.
BACKGROUND: Streptococci involved in infective endocarditis (IE) primarily comprise alpha- or non-hemolytic streptococci (ANHS). Moreover, beta-hemolytic streptococci (BHS) can be involved, and guidelines recommend the addition of gentamicin for the first 2 weeks of treatment and the consideration of early surgery in such cases. This study compared the morbidity and mortality associated with IE depending on the microorganisms involved (BHS, ANHS, staphylococci, and enterococci). METHODS: We conducted a retrospective observational study between 2012 and 2017 in a single hospital in France. The endpoints were overall in-hospital mortality, 1-year mortality and the occurrence of complications. RESULTS: We analyzed 316 episodes of definite IE including 150 (38%), 96 (25%), 46 (12%), and 24 cases (6%) of staphylococcal, ANHS, enterococcal, and BHS IE, respectively. In-hospital mortality was significantly higher in the staphylococcal (n = 40; 26.7%) and BHS groups (n = 6; 25.0%) than in the ANHS (n = 9; 9.4%) and enterococcal groups (n = 5; 10.9%) (all p < 0.01). The rates of septic shock and cerebral emboli were also higher in the BHS group than in the ANHS group [n = 7 (29.2%) vs. n = 3 (3.1%), p < 0.001; n = 7 (29.2%) vs. n = 12 (12.5%); p = 0.05, respectively]. CONCLUSION: This study confirmed that BHS IE has a more severe prognosis than ANHS IE. The virulence of BHS may be similar to that of staphylococci, justifying increased monitoring of these patients and more 'aggressive' treatments such as early surgery.
Authors: Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus Journal: JAMA Date: 2016-02-23 Impact factor: 56.272
Authors: Radka Ivanova-Georgieva; Josefa Ruiz-Morales; Emilio García-Cabrera; María Victoria García-López; Juan Gálvez-Acebal; Antonio Plata-Ciezar; Javier de la Torre Lima; Carmen Hidalgo-Tenorio; Francisco Javier Martínez-Marcos; David Vinuesa García; Rafael Luque; Arístides de Alarcón González Journal: Eur J Clin Microbiol Infect Dis Date: 2018-11-14 Impact factor: 3.267
Authors: A Sambola; J M Miro; M P Tornos; B Almirante; A Moreno-Torrico; M Gurgui; E Martinez; A Del Rio; M Azqueta; F Marco; J M Gatell Journal: Clin Infect Dis Date: 2002-05-24 Impact factor: 9.079
Authors: Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert Journal: Circulation Date: 2015-09-15 Impact factor: 29.690
Authors: Andrew Wang; Eugene Athan; Paul A Pappas; Vance G Fowler; Lars Olaison; Carlos Paré; Benito Almirante; Patricia Muñoz; Marco Rizzi; Christoph Naber; Mateja Logar; Pierre Tattevin; Diana L Iarussi; Christine Selton-Suty; Sandra Braun Jones; José Casabé; Arthur Morris; G Ralph Corey; Christopher H Cabell Journal: JAMA Date: 2007-03-28 Impact factor: 56.272
Authors: Leandro Slipczuk; J Nicolas Codolosa; Carlos D Davila; Abel Romero-Corral; Jeong Yun; Gregg S Pressman; Vincent M Figueredo Journal: PLoS One Date: 2013-12-09 Impact factor: 3.240